| Biomarker ID | 1417 |
| PMID | 24741114 |
| Year | 2014 |
| Biomarker | NAAA |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in GS >7 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: TRPM6 human kinase ARCHS4 coexpression, PHKG2 human kinase ARCHS4 coexpression, STK32C human kinase ARCHS4 coexpression |
| Experiment | Gleason Score ≤ 7 and Gleason Score >7 |
| Type of Biomarker | Prognostic |
| Cohort | TMA analysis was performed with 56 prostate adenocarcinoma cases. Each case contained four cores of tumor and two cores of patient-matched adjacent normal tissue. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.743 |
| Accuracy | NA |
| Level Of Significance | p <0.05 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |